Mutant selection window hypothesis updated

Clinical Infectious Diseases

Volumn 44, Issue 5, 2007, Pages 681-688

  Drlica, Karl ^a   Zhao, Xilin ^a  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; BACTERIAL CELL; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; CELLS, CULTURED; DRUG RESISTANCE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MUTATION; SELECTION (GENETICS);

EID: 33847045214     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/511642     Document Type: Review

References (68)

1. Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges, and responses. Nature Med 2004; 10:S122-9.
2. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis 2001; 33(Suppl 3):S147-56.
3. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: measurement and potential uses of the mutant selection window. J Infect Dis 2002; 185:561-5.
4. Dong Y, Zhao X, Domagala J, Drlica K. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43:1756-8.
5. Ambrose P, Zoe-Powers A, Russo R, Jones D, Owens R. Utilizing pharmacodynamics and pharmacoeconomics in clinical and formulary decision making. In: Nightingale C, Murakawa T, Ambrose P, eds. Antimicrobial pharmacodynamics in theory and clinical practice. New York: Marcel Dekker, 2002:385-409.
6. Stratton C. Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance. Emerg Infect Dis 2003; 9:10-6.
7. Davidson R, Cavalcanti R, Brunton J, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346:747-50.
8. Sieradzki K, Leski T, Dick J, Borio L, Tomasz A. Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherapy. J Clin Microbiol 2003; 41:1687-93.
9. Sieradzki K, Roberts R, Haber S, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999; 340:517-23.
10. Zhou J, Dong Y, Zhao X, et al. Selection of antibiotic resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations. J Infect Dis 2000; 182:517-25.
11. Sindelar G, Zhao X, Liew A, et al. Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria. Antimicrob Agents Chemother 2000; 44:3337-43.
12. Drlica K, Zhao X, Wang J-Y, et al. An anti-mutant approach for antimicrobial use. In: Fong I, Drlica K, eds. Antimicrobial resistance and implications for the 21st century. (In press).
13. Hansen GT, Zhao X, Drlica K, Blondeau JM. Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa. Int J Antimicrob Agents 2006; 27:120-4.
14. Lu T, Zhao X, Li X, Hansen G, Blondeau J, Drlica K. Effect of chloramphenicol, erythromycin, moxifloxacin, penicillin, and tetracycline concentration on the recovery of resistant mutants of Mycobacterium smegmatis and Staphylococcus aureus. J Antimicrob Chemother 2003; 52:61-4.
15. Li X, Zhao X, Drlica K. Selection of Streptococcus pneumoniae mutants having reduced susceptibility to levofloxacin and moxifloxacin. Antimicrob Agents Chemother 2002; 46:522-4.
16. Spratt GG. Resistance to antibiotics mediated by target alterations. Science 1994; 264:388-93.
17. Chambers HF. Penicillin-binding protein-mediated resistance in pneumococci and staphylococci. Clin Microbiol Rev 1997; 10:781-91.
18. Poole K. Resistance to β-lactam antibiotics. Cell Mol Life Sci 2004; 61:2200-23.
19. Hovde L, Rotschafer S, Ibrahim K, Gunderson B, Hermsen E, Rotschafer J. Mutation prevention concentration of ceftriaxone, meropenem, imipenem, and ertapenem against three strains of Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2003; 45:265-7.
20. Dong Y, Zhao X, Kreiswirth B, Drlica K. Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000; 44:2581-4.
21. Sande M, Mandell G. Effect of rifampicin on nasal carriage of Staphylococcus aureus. Antimicrob Agents Chemother 1975; 7:294-7.
22. Binda G, Domenichini A, Gottardi A, et al. Rifampicin, a general review. Arzneimittelforschung 1971; 21:1908-77.
23. Sanders C. Mechanisms responsible for cross-resistance and dichotomous resistance among the quinolones. Clin Infect Dis 2001; 32(Suppl 1):S1-8.
24. Marcusson L, Olofsson S, Lindgren P, Cars O, Hughes D. Mutant prevention concentration of ciprofloxacin for urinary tract infection isolates of Escherichia coli. J Antimicrob Chemother 2005; 55:938-43.
25. Drlica K, Zhao X, Blondeau J, Hesje C. Low correlation between minimal inhibitory concentration (MIC) and mutant prevention concentration (MPC). Antimicrob Agents Chemother 2006; 50:403-4.
26. Campion J, McNamara P, Evans M. Pharmacodynamic modeling of ciprofloxacin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49:209-19.
27. Tam V, Louie A, Deziel M, Liu W, Leary R, Drusano G. Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa. J Infect Dis 2005; 192:420-8.
28. Jumbe N, Louie A, Leary R, et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 2003; 112:275-85.
29. Blondeau J, Zhao X, Hansen G, Drlica K. Mutant prevention concentrations (MPC) or fluoroquinolones with clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001; 45:433-8.
30. Blondeau J, Hansen G, Metzler K, Hedlin P. The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration. J Chemother 2004; 16(Suppl 3):1-19.
31. Firsov A, Vostrov S, Lubenko I, Drlica K, Portnoy Y, Zinner S. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis: four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:1604-13.
32. Zinner S, Lubenko I, Gilbert D, et al. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentration in and out of the mutant selection window: related changes in susceptibility, resistance frequency, and bacterial killing. J Antimicrob Chemother 2003; 52:616-22.
33. Campion J, Chung P, McNamara P, Titlow W, Evans M. Pharmacodynamic modeling of the evolution of levofloxacin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49:2189-99.
34. Campion J, McNamara P, Evans ME. Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments. Antimicrob Agents Chemother 2004; 48:4733-44.
35. Firsov A, Smirnova M, Lubenko I, Vostrov S, Portnoy Y, Zinner S. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. J Antimicrob Chemother 2006; 58:1185-92.
36. Baquero F, Negri M. Strategies to minimize the development of antibiotic resistance. J Chemother 1997; 9(Suppl 3):29-37.
37. Mouton J, Dudley M, Cars O, Derendorf H, Drusano G. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 2005; 55:601-7.
38. Craig WA. Pharmacodynamics of antimicrobials: general concepts and applications. In: Nightingale C, Murakawa T, Ambrose P, eds. Antimicrobial pharmacodynamics in theory and clinical practice. New York: Marcel Dekker, 2002:1-22.
39. Olofsson S, Marcusson L, Komp-Lindgren P, Hughes D, Cars O. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. J Antimicrob Chemother 2006; 57:1116-21.
40. Andes D, Craig W. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. Antimicrob Agents Chemother 2002; 46:1665-70.
41. Etienne M, Croisier D, Charles P-E, et al. Effect of low-level resistance on subsequent enrichment of fluoroquinolone-resistant Streptococcus pneumoniae in rabbits. J Infect Dis 2004; 190:1472-5.
42. Croisier D, Etienne M, Piroth L, et al. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of quinolone resistance on the enrichment of resistant mutants. J Antimicrob Chemother 2004; 54:640-7.
43. Cui J, Liu Y, Wang R, Tong W, Drlica K, Zhao X. The mutant selection window demonstrated in rabbits infected with Staphylococcus aureus. J Infect Dis 2006; 194:1601-8.
44. Liu Y, Cui J, Wang R, Wang X, Drlica K, Zhao X. Selection of rifampicin-resistant Staphylococcus aureus during tuberculosis therapy: concurrent bacterial eradication and acquisition of resistance. J Antimicrob Chemother 2005; 56:1172-5.
45. Lipsitch M, Levin B. The population dynamics of antimicrobial chemotherapy. Antimicrob Agents Chemother 1997; 41:363-73.
46. Shockley T, Hotchkiss R. Stepwise introduction of transformable penicillin resistance in pneumococcus. Genetics 1970; 64:397-408.
47. Eliopoulos G, Gardella A, Moellering JR. In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent. Antimicrob Agents Chemother 1984; 25:331-5.
48. Li X, Mariano N, Rahal JJ, Urban CM, Drlica K. Quinolone-resistant Haemophilus influenzae: determination of mutant selection window for ciprofloxacin, garenoxacin, levofloxacin, and moxifloxacin. Antimicrob Agents Chemother 2004; 48:4460-2.
49. Thomas J, Forrest A, Bhavnani S, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42:521-7.
50. Baquero F. Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption? J Chemother 1999; 11(Suppl 1):35-43.
51. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet 1999; 353:1843-7.
52. Hall RM. Mobile gene cassettes and integrons: moving antibiotic resistance genes in gram-negative bacteria. Ciba Found Symp 1997; 207:192-202.
53. Michael CA, Gillings M, Holmes A, et al. Mobile gene cassettes: a fundamental resource for bacterial evolution. Am Nat 2004; 164:1-12.
54. Chopra I, O'Neill A, Miller K. The role of mutators in the emergence of antibiotic-resistant bacteria. Drug Resistance Updates 2003; 6:137-45.
55. Oliver A, Levin B, Juan C, Baquero F, Blazquez J. Hypermutation and the preexistence of antibiotic-resistant Pseudomonas aeruginosa mutants: implications for susceptibility testing and treatment of chronic infections. Antimicrob Agents Chemother 2004; 48:4226-33.
56. Discotto LF, Lawrence L, Denbleyker K, Barrett JF. Staphylococcus aureus mutants selected by BMS-284756. Antimicrob Agents Chemother 2001; 45:3273-5.
57. Fung-Tomc J, Valera L, Minassian B, Bonner D, Gradelski E. Activity of the novel des-fluoro(6) quinolone BMS-284756 against methicillin-susceptible and -resistant staphylococci. J Antimicrob Chemother 2001; 48:735-48.
58. Jones R, Pfaller M, Stilwell M. Activity and spectrum of BMS 284756, a new des-F(6) quinolone, tested against strains of ciprofloxacin-resistant gram-positive cocci. SENTRY Antimicrobial Surveillance Program Participants Group. Diagn Microbiol Infect Dis 2001; 39:133-5.
59. Weller T, Andrews J, Jevons G, Wise R. The in vitro activity of BMS-2847676, a new des-fluorinated quinolone. J Antimicrob Chemother 2002; 49:177-84.
60. Acar J, Goldstein F. Trends in bacterial resistance to fluoroquinolones. Clin Infect Dis 1997; 24:S67-73.
61. Tillotson G, Zhao X, Drlica K. Fluoroquinolones as pneumococcal therapy: closing the barn door before the horse escapes. Lancet Infect Dis 2001; 1:145-6.
62. Zhao X, Eisner W, Perl-Rosenthal N, Kreiswirth B, Drlica K. Mutant prevention concentration for garenoxacin (BMS-284756) with ciprofloxacin- susceptible and ciprofloxacin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:1023-7.
63. Gajjar D, Bello A, Ge Z, Christopher L, Grasela D. Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects. Antimicrob Agents Chemother 2003; 47:2256-63.
64. Drlica K. The mutant selection window and antimicrobial resistance. J Antimicrob Chemother 2003; 52:11-7.
65. Firsov A, Vostrov S, Lubenko I, Arzamastsev A, Portnoy Y, Zinner S. ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model. J Antimicrob Chemother 2004; 54:178-86.
66. Firsov A, Vostrov S, Lubenko I, Zinner S, Portnoy Y. Concentration- dependent changes in the susceptibility and killing of Staphylococcus aureus in an in vitro dynamic model that simulates normal and impaired gatifloxacin elimination. Int J Antimicrob Agents 2004; 23:60-6.
67. Gonzalez M, Uribe F, Moisen S, et al. Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother 1984; 26:741-4.
68. Baquero F. Low-level antibacterial resistance: a gateway to clinical resistance. Drug Resist Updat 2001; 4:93-105.